ResMed Inc. (RMD) is set to announce its latest quarterly earnings on Wednesday, April 29th, with a consensus estimate of $2.79 EPS.
ResMed Inc. (RMD) is currently priced at $221.68, reflecting a slight decrease of 0.153% from the previous close. Trading volume stands at $156,900, representing a 14.07% deviation from the average.
In the last quarterly report on Wednesday, January 28th, ResMed Inc. (RMD) surpassed expectations with an EPS of $2.69.
With a forward dividend yield of 1.08%, ResMed Inc. (RMD) distributed 60 cents per share MRQ, showing a year-over-year increase.
ResMed Inc. (RMD) generated a free cash flow of $311.21 million, with a net change in cash of $33.22 million, ending the period with $1.42 billion in cash reserves.
The company reported a net income of $392.59 million, translating to an EPS of $2.69. Operating income stood at $497.60 million, with a gross profit of $884.66 million.
Key ratios for ResMed Inc. (RMD) include a net profit margin of 27.59%, return on assets of 4.62%, and a price-to-earnings ratio of 22.47.
ResMed Inc. (RMD) shows strong financial health with total assets amounting to $8.50 billion, including $1.42 billion in cash and cash equivalents.
This real-time financial report provides insights into ResMed Inc.'s current performance and financial standing.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME)to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; and HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies. The company markets its products primarily to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.